It is vital to acknowledge early symptoms, seek specialized care, as well as an expert opinion when it comes to gastrointestinal stromal tumor treatment. It is vital to pay attention to your body and ...
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions. Dr. Breelyn Wilky, an associate professor of ...
CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment ...
Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...
The optimal duration of adjuvant imatinib has yet to be determined, and clinical trials are ongoing to address this. KIT-directed tyrosine kinase inhibitors (TKIs) are the key treatment for advanced ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
Gastrointestinal stromal tumours (GISTs) are rare stomach tumours driven by KIT or PDGFRA gene mutations. Unlike typical gastric cancers, they respond well to targeted therapy such as imatinib. Early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results